S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
NASDAQ:MGNX

MacroGenics - MGNX Stock Forecast, Price & News

$5.77
+0.15 (+2.67%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.58
$5.86
50-Day Range
$5.17
$6.92
52-Week Range
$2.13
$12.79
Volume
559,843 shs
Average Volume
541,457 shs
Market Capitalization
$354.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.56

MacroGenics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
65.6% Upside
$9.56 Price Target
Short Interest
Bearish
7.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.54mentions of MacroGenics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$4.88 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.48) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

222nd out of 1,055 stocks

Pharmaceutical Preparations Industry

107th out of 518 stocks


MGNX stock logo

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Why Shares of MacroGenics Were Dropping Tuesday
Why MacroGenics Stock Crushed the Market on Monday
MacroGenics (MGNX) Q3 2022 Earnings Call Transcript
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
427
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$9.56
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+65.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

Net Income
$-202,120,000.00
Net Margins
-204.95%
Pretax Margin
-204.95%

Debt

Sales & Book Value

Annual Sales
$77.45 million
Book Value
$3.91 per share

Miscellaneous

Free Float
56,618,000
Market Cap
$354.68 million
Optionable
Optionable
Beta
2.04

Social Links


Key Executives

  • Scott E. Koenig
    President, Chief Executive Officer & Director
  • Eric Risser
    Chief Operating Officer
  • James KarrelsJames Karrels
    Chief Financial Officer, Secretary & Senior VP
  • Ezio Bonvini
    Chief Scientific Officer & Senior VP-Research
  • Stephen L. Eck
    Chief Medical Officer & SVP-Clinical Development













MGNX Stock - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price forecast for 2023?

10 analysts have issued 12 month price targets for MacroGenics' shares. Their MGNX share price forecasts range from $5.00 to $16.00. On average, they anticipate the company's share price to reach $9.56 in the next year. This suggests a possible upside of 68.8% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2023?

MacroGenics' stock was trading at $6.71 at the beginning of 2023. Since then, MGNX shares have decreased by 15.6% and is now trading at $5.66.
View the best growth stocks for 2023 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) announced its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. The biopharmaceutical company had revenue of $41.73 million for the quarter, compared to the consensus estimate of $22.74 million. MacroGenics had a negative trailing twelve-month return on equity of 111.57% and a negative net margin of 204.95%.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.43%), Pinnacle Associates Ltd. (0.60%), Hennion & Walsh Asset Management Inc. (0.06%), New York State Common Retirement Fund (0.06%), Allspring Global Investments Holdings LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $5.66.

How much money does MacroGenics make?

MacroGenics (NASDAQ:MGNX) has a market capitalization of $347.92 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does MacroGenics have?

The company employs 427 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 2/1/2023 by MarketBeat.com Staff